Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Pharma PLC Warrant

0.0442
0.0000
Volume:- -
Turnover:4.42
Market Cap:- -
PE:- -
High:0.0442
Open:0.0442
Low:0.0442
Close:0.0442
Loading ...

NASDAQ TRADE HALT HALT NEWS PENDING AT 10:30 AM

Reuters
·
29 Jun 2022

4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

Business Wire
·
29 Jun 2022

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire
·
27 May 2022

4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference

Business Wire
·
17 May 2022

4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

Business Wire
·
01 Apr 2022

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

Business Wire
·
23 Mar 2022

4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease

Business Wire
·
22 Feb 2022

4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma

Business Wire
·
27 Jan 2022

How Much Of 4D pharma plc (LON:DDDD) Do Insiders Own?

Simply Wall St.
·
22 Jan 2022

4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004

Business Wire
·
20 Jan 2022

4D pharma appoints John Doyle as Chief Financial Officer

Business Wire
·
03 Jan 2022

4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma

Business Wire
·
13 Dec 2021

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021

Business Wire
·
09 Dec 2021

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

GlobeNewswire
·
19 Nov 2021

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

GlobeNewswire
·
15 Nov 2021

4D pharma to Participate in Jefferies London Healthcare Conference

Business Wire
·
11 Nov 2021

4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021

Business Wire
·
15 Sep 2021

4D pharma to Participate in Upcoming Virtual Investor Conferences in September

Business Wire
·
09 Sep 2021

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

Business Wire
·
02 Aug 2021